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Over the last decade, substantial scientific evidence has accumulated that indicates contamination of en-
vironmental surfaces in hospital rooms plays an important role in the transmission of key health care–
associated pathogens (eg, methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, 
Clostridium difficile, Acinetobacter spp). For example, a patient admitted to a room previously occupied 
by a patient colonized or infected with one of these pathogens has a higher risk for acquiring one of these 
pathogens than a patient admitted to a room whose previous occupant was not colonized or infected. 
This risk is not surprising because multiple studies have demonstrated that surfaces in hospital rooms 
are poorly cleaned during terminal cleaning. To reduce surface contamination after terminal cleaning, 
no touch methods of room disinfection have been developed. This article will review the no touch methods, 
ultraviolet light devices, and hydrogen peroxide systems, with a focus on clinical trials which have used 
patient colonization or infection as an outcome.
Multiple studies have demonstrated that ultraviolet light devices and hydrogen peroxide systems have 
been shown to inactivate microbes experimentally plated on carrier materials and placed in hospital rooms 
and to decontaminate surfaces in hospital rooms naturally contaminated with multidrug-resistant patho-
gens. A growing number of clinical studies have demonstrated that ultraviolet devices and hydrogen peroxide 
systems when used for terminal disinfection can reduce colonization or health care–associated infec-
tions in patients admitted to these hospital rooms.
.
Health care–associated infections (HAIs) remain an important
source of patient morbidity and mortality. Based on a large sample
of U.S. acute care hospitals, approximately 4% of patients on any given
day have at least 1 HAI.1 Overall, there were an estimated 722,000
HAIs in U.S. acute care hospitals in 2011; approximately 75,000 hos-
pital patients with an HAI died during their hospitalization. It has
been estimated that the source of pathogens causing an HAI in the
intensive care unit was the patients’ endogenous flora (40%-60%);
cross-infection via the hands of health care personnel (HCP; 20%-
40%); antibiotic-driven changes in flora (20%-25%); and other
(including contamination of the environment; 20%).2 Further, con-
tamination of the hands of HCP could result directly from patient
contact or indirectly from touching contaminated environmental
surfaces.3 It has been shown that the gloves or hands of HCP are
just as likely to become contaminated from touching a patient as
touching an environmental surface in a patient’s room.4,5
Over the last decade, substantial scientific evidence has accu-
mulated that contamination of environmental surfaces in hospital
rooms plays an important role in the transmission of several key
health care–associated pathogens, including methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resistant enterococci
(VRE), Clostridium difficile, Acinetobacter spp, and norovirus.6-11 In
general, all of these pathogens share the following characteristics:
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ability to survive for prolonged periods of times on environmen-
tal surfaces, ability to remain virulent after environmental exposure,
frequent contamination of the hospital environment, ability to col-
onize patients, ability to transiently colonize the hands of HCP, and
transmission via the contaminated hands of HCP.8 Norovirus and
C difficile also are noted for a small inoculating dose and relative
resistance to antiseptics and disinfectants used on environmental
surfaces. Evidence supporting the role of the contaminated surface
environment in the transmission of several key health care–
associated pathogens is summarized as follows:
• The surface environment in rooms of colonized or infected pa-
tients is frequently contaminated with the pathogen.
• The pathogen is capable of surviving on hospital room sur-
faces and medical equipment for a prolonged period of time.
• Contact with hospital room surfaces or medical equipment by
HCP frequently leads to contamination of hands or gloves.
• The frequency with which room surfaces are contaminated cor-
relateswith the frequencyof handor glove contaminationof HCP.
• The patient admitted to a room previously occupied by a patient
colonized or infected with a pathogen (eg, MRSA, VRE, C difficile,
Acinetobacter spp) has an increased likelihood of developing col-
onization or infection with that pathogen.
• Improved terminal cleaning of rooms leads to a decreased rate
of individual patient colonization and infection.
• Improved terminal cleaning of rooms leads to a decreased
facility-wide rate of colonization and infection.
• Improved terminal disinfection with a no touchmethod leads to
a decreased rate of infection in patients subsequently admitted
to a room where the prior occupant was colonized or infected.
• Improved terminal disinfection with a no touch method leads
to a decreased rate of facility-wide colonization and infection.
This article will review no touch methods for terminal room dis-
infection, specifically ultraviolet (UV) light devices or hydrogen
peroxide systems, with a focus on studies that have assessedwhether
use of these technologies has been demonstrated to reduce HAIs.
RATIONALE FOR USING A NO TOUCH METHOD FOR TERMINAL
ROOM DISINFECTION
Multiple studies have demonstrated that surfaces in hospital
rooms are poorly cleaned during terminal cleaning. Although
methods of assessing the adequacy of cleaning varied (ie, visibly
clean, adenosine triphosphate bioluminescence, fluorescent dye,
aerobic plate counts), several studies have demonstrated that <50%
of room surfaces were properly cleaned.12-18 Several reviews have
concluded that improved cleaning leads to reductions in HAI.11,19
However, there is a paucity of high-quality studies demonstrating
that improved cleaning and disinfection reduces HAIs.20,21 Impor-
tantly, the studies that have assessed interventions to improve
cleaning have reported that after the intervention, approximately
5%-30% of surfaces remain potentially contaminated.12-18
Because of the demonstrated failure of interventions to achieve
consistent and high rates of cleaning and disinfection of room sur-
faces, new no touch methods of room disinfection have been
developed. The most promising no touch methods use either UV
light devices or hydrogen peroxide systems.22-24
UV LIGHT DEVICES FOR TERMINAL ROOM DECONTAMINATION
Background
UV irradiation has been used for control of pathogenic microor-
ganisms in a variety of applications, such as control of legionellosis,
and disinfection of air, surfaces, and instruments.22 At certain wave-
lengths, UV light will break the molecular bonds in DNA, thereby
destroying the organism.Most UV roomdisinfection devices use UV-C
irradiation which has a characteristic wavelength of 200-270 nm (eg,
254 nm) that lies in the germicidal active portion of the electromag-
netic spectrum of 200-320 nm. Another UV device uses pulsed-
xenon radiation,which produces UV light in the 200- to 320-nm range.
The efficacy of UV irradiation devices used for hospital room dis-
infection is a function of many parameters, including organic load,
pathogen, intensity, dose, distance from the device, exposure time,
direct line of sight from device or shaded exposure, lamp place-
ment, room size and shape, and surface. Few studies have
systematically investigated how these parameters affect the effec-
tiveness of UV irradiation. Nerandzic et al studied 2 UV room
disinfection devices (Tru-D [Tru-D SmartUVC, Memphis, TN] and
PATHOGON® [STERIS, Mentor, OH]) and reported the following: (1)
pathogen concentration did not significantly impact the killing ef-
ficacy of the devices; (2) both a heavy and light organic load had a
significant negative impact on the killing efficacy of the devices; and
(3) increasing the distance to ~3.05 m from the devices reduced the
killing efficacy to ≤3 log10 colony forming units/cm2 for MRSA and
VRE and <2 log10 colony forming units/cm2 for C difficile spores.25
Cadnum et al studied how various parameters affected the effec-
tiveness of a UV-C device (Optimum-UV™, Clorox, Oakland, CA) and
reported the following: (1) spreading the inoculum over a greater
surface area significantly enhanced killing of MRSA and C difficile;
(2) orientation of the carrier disks in parallel rather than perpen-
dicular with the UV-C enhanced killing; (3) presence of an organic
load also impacted the measured efficacy of UV-C under certain test
conditions; (4) use of plastic, formica, and glass slides resulted in
similar killing when compared with steel carrier disks, provided
manual spreading was used; and (5) heights from floor level to
6 ft did not affect killing at 1.83 m using Optimum.26
UV device effectiveness to reduce intentionally contaminated sites
Multiple studies have assessed the effectiveness of UV devices
to inactivate microbes inoculated onto various test surfaces which
are then placed in a typical hospital room (Table 1).27-33 In general,
the inoculating doses were >4 log10 in order to fully assess the level
of bacterial inactivation. Themost commonly tested organisms were
epidemiologic important health care–associated pathogens and in-
cluded MRSA, VRE, C difficile, and Acinetobacter spp.
One can conclude the following from the reported results: (1) > 3
log10 vegetative organisms can be killed in 5-25 minutes by UV-C;
(2) it requires greater time and energy to kill a spore-forming or-
ganism, such as C difficile; (3) the level of inactivation of pulsed xenon
may be less than for UV-C; however, this is based on a limited
number of published results; and (4) the level of inactivation on
surfaces in direct line of sight of the UV device may be up to 2 log10
greater than for C difficile not in the direct line of sight. There appears
to be substantial consistency across many studies regarding the ef-
fectiveness of UV-C; however, most studies have used the same
device (ie, Tru-D), and only a few of the UV devices commercially
available have actually been studied. The time needed to inacti-
vate pathogens has been demonstrated to be shortened by use of
UV reflective wall paint for multiple different UV-C devices.30,32
UV device effectiveness to reduce actual contaminated sites
Multiple studies have assessed the effectiveness of UV devices
to decontaminate actual hospital rooms after discharge of a patient
colonized or infected with a multidrug-resistant pathogen
(Table 2).27,33-37 Pathogens evaluated included MRSA, VRE,
Acinetobacter spp, and C difficile. Cycle times for vegetative
bacteria ranged from 10-25 minutes, and for C difficile cycle times
ranged from 10-45 minutes. In all cases the frequency of positive
surface sites post-treatment was <11%, and in many cases it was
<1%. The reported log10 reductions were always <2.
It is important to understand that the bioburden on contami-
nated surfaces in hospital rooms is relatively low; therefore, the
reduction in frequency of positive surface sites is a better measure
of UV effectiveness than the log10 reduction.
HYDROGEN PEROXIDE SYSTEMS FOR TERMINAL
ROOM DECONTAMINATION
Background
Hydrogen peroxide is an oxidizing agent which produces highly
reactive hydroxyl radicals that attack DNA, membrane lipids, and
other essential cell components.38
Twomajor types of hydrogen peroxide room disinfection systems
are generally available: aerosolized hydrogen peroxide (aHP) systems
(eg, GLOSAIR; Advanced Sterilization Products, Irvine, CA, previ-
ously Sterinis; BioGienie; Steris, Mentor, OH; Nocospray; Oxy’pharm,
Champigny-sur-Marne, France) and H2O2 vapor systems (eg, Bioquell,
Andover, Hampshire, UK; VHP Biodecontamination Systems; Steris,
Mentor, OH). H2O2 room disinfection systems have been
reviewed.24,39,40 The H2O2 vapor systems use 30%-35% H2O2. The Steris
VHP system requires approximately 8 hours for disinfection, whereas
the Bioquell hydrogen peroxide vapor (HPV) system requires 1.5-
2.5 hours. The aHP systems combine 5%-7% H2O2 with <50 ppm Ag
cations. Process time is 2-3 hours.
Hydrogen peroxide systems effectiveness to inactive microbes
Only limited data are available on the activity of aHP systems
based on laboratory studies or evaluation of experimentally con-
taminated carriers assessed in hospital rooms. An aHP system
(Sterinis) was able to kill >4 log10 MRSA and Acinetobacter spp
using a carrier test in a hospital room.41 Another study reported a
1.0-1.7 log10 reduction of experimentally contaminated surfaces
with VRE in a hospital room.42 No significant decontamination of
Mycobacterium tuberculosis was observed when the aHP system
(Sterinis) was used to decontaminate a test surface contaminated
with air-dried M tuberculosis.43 When used in an operating
department, 3 cycles of H2O2 aerosol (Sterinis) were required to
kill Bacillus atrophaeus spore strips (4-5 hours); 2 cycles were
ineffective.44
The effectiveness of H2O2 vapor systems has been well studied.
For example, a hydrogen peroxide device (Bioquell) was tested for
its microbiologic efficacy in a purpose-built room where nosoco-
mial pathogens had been inoculated onto disks and allowed to dry
over varying amounts of time. All pathogens were inactivated within
90 minutes of exposure to HPV.45 Similarly, the same system was
evaluated in an operating room using experimentally contami-
nated carriers; the device inactivated all spore biologic indicators
(Geobacillus stearothermophilus; >6 log10 reduction), and no MRSA,
VRE, or multidrug-resistant A baumanniiwere recovered from stain-
less steel and cotton carriers (>4-5 log10 reduction, depending on
the starting inoculum).46 Multiple studies have demonstrated ex-
cellent sporicidal activity, and the system has been shown to
inactivate a number of important viruses, including feline calicivirus
(surrogate for human norovirus), human adenovirus type 1, severe
acute respiratory syndrome coronavirus, and several viruses of vet-
erinary importance.47 Inactivation (>3 log10) of a nonenveloped virus
(MS2) occurred within 30minutes.48 In the presence of large protein
loads, inactivation is slower.48
Hydrogen peroxide systems effectiveness to reduce actual
contaminated sites
Multiple studies have demonstrated the ability of hydrogen
peroxide systems to reduce multidrug-resistant organisms
Table 1
Effectiveness of UV devices on reducing MDROs on carriers
Author, year UV system MDROs Time (min) Energy (μW/cm2) Log10 reduction direct (indirect)
Rutala, 201027 UV-C, Tru-D MRSA, VRE, A ~15 12,000 4.31 (3.85), 3.90 (3.25), 4.21 (3.79)
Rutala, 201027 UV-C, Tru-D Cd ~50 36,000 4.04 (2.43)
Boyce, 201128 UV-C, Tru-D Cd 67.8 (1 stage) 22,000 1.7-2.9
Havill, 201229 UV-C, Tru-D Cd 73 (mean) 22,000 2.2
Rutala, 201330 UV-C, Tru-D MRSA 25 12,000 4.71 (4.27)
Rutala, 201330 UV-C, Tru-D Cd 43 22,000 3.41 (2.01)
Mahida, 201331 UV-C, Tru-D OR: MRSA, VRE 49 12,000 ≥4.0 (≥4.0), 3.5 (2.4)
Mahida, 201331 UV-C, Tru-D Single patient room: VRE, A, As 23-93 12,000 ≥4.0 (>2.3), ≥4.0 (1.7), ≥4.0 (2.0)
Rutala, 201432 UV-C, Optimum MRSA 5 NS 4.10 (2.74)
Rutala, 201432 UV-C, Optimum Cd 10 NS 3.35 (1.80)
Nerandzic, 201533 UV, PX, Xenon Cd, MRSA, VRE 10 at 4 ft (2 cycles) NS 0.55, 1.85, 0.6
A, Acinetobacter spp; As, Aspergillus; Cd, Clostridium difficile; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; NS, not stated; OR, op-
erating room; PX, pulsed xenon; UV, ultraviolet light; VRE, vancomycin-resistant enterococci.
Table 2
Effectiveness of UV devices on reducing MDROs in contaminated patient rooms
Author, year UV system MDROs Time (min); energy (μW/cm2) Positive sites (before and after) (%) Log10 reduction
Rutala, 201027 UV-C, Tru-D MRSA ~15; 12,000 20.2, 0.5 1.30
Nerandzic, 201034 UV-C, Tru-D MRSA, VRE 20; 12,000 10.7, 0.8; 2.7, 0.38 0.68; 2.52
Nerandzic, 201034 UV-C, Tru-D Cd 45; 22,000 3.4, 0.38 1.39;
Stibich, 201135 UV, PX, Xenex VRE 12; NS 8.2, 0 1.36
Anderson, 201336 UV-C, Tru-D All, VRE, A 25; 12,000 NS; 11, 1; 13, 3 1.35; 1.68; 1.71
Anderson, 201336 UV-C, Tru-D Cd 45; 22,000 10, 5 1.16
Jinadatha, 201537 UV, PX, Xenex MRSA 15 (3 cycles of 5 min), NS 70, 8 2.0
Nerandzic, 201533 UV, PX, Xenex MRSA, VRE, Cd 10 (2 cycles of 5 min); NS 10, 2; 4, 0.9; 19, 8 0.90, 1.08, NS
Jinadatha, 201537 UV-PX, Xenex MRSA 15 (3 cycles of 5 min); NS NS, NS 0.63
A, Acinetobacter spp; All, all target organisms; Cd, Clostridium difficile;MDRO, multidrug-resistant organism;MRSA, methicillin-resistant Staphylococcus aureus; NS, not stated;
PX, pulsed xenon; UV, ultraviolet light; VRE, vancomycin-resistant enterococci.
contaminating surfaces in hospital rooms (Table 3).49-58 The device
used in most of these studies was a HPV device (Bioquell). In most
of the studies, the number of contaminated surfaces was reduced
to 0% and in all cases to <5%. Of note, none of the studies de-
scribed the log10 reduction in pathogens.
COMPARATIVE TRIALS USING NO TOUCH ROOM
DECONTAMINATION DEVICES
Most of the studies in the literature have only assessed a single
type of room decontamination device. However, several studies have
assessed different devices using the same methodology, com-
pared devices using different methodologies, or compared a room
decontamination device with chemical disinfection.
Holmdahl et al compared a HPV system (Bioquell) with an aHP
system (Sterinis).59 All biologic spores and microbial load indica-
tors were inactivated for the 3 HPV tests, compared with only 10%
in the first aHP test and 79% in the other 2 aHP tests. In a similar
comparison, Fu et al reported that the HPV system inactivated >90%
of the 6 log10 biologic indicators (BIs) containing G stearothermophilus
and >95% of the 4 log10 BIs.60 In contrast, the aHP system inacti-
vated <10% of the pouched 6 log10 BIs, <15% of the unpouched BIs,
and approximately 1/3 of the 4 log10 BIs, regardless of whether they
were pouched or unpouched.
French et al compared room cleaning without use of a disinfec-
tant to HPV decontamination and reported HPV was superior in
eliminatingMRSA.49 Ghantoji et al compared a pulsed-xenon system
with 10% dilution of bleach for decontamination of C difficile rooms
and found there were no significant differences in final contami-
nation levels between the 2 methods of decontamination.61 Barbut
et al compared the effectiveness of 0.5% hypochlorite to a hydro-
gen peroxide dry-mist device (Sterinis) for the disinfection of rooms
of patients with C difficile and reported a 50% decrease in C difficile
contamination after hypochlorite compared with a 91% reduction
after hydrogen peroxide decontamination (P < .005).62 Impor-
tantly, there was no assessment of the effectiveness of cleaning.
Nerandzic et al compared 2 UV-C devices (Tru-D and PATHOGON)
in a laboratory setting.25 Both devices were equally effective for killing
C difficile spores, MRSA, and VRE. Rutala et al using the samemethods
studied 2 different UV-C devices.30,32 For MRSA, one device (Tru-
D) required approximately 25minutes for inactivation comparedwith
the other device (Optimum), which required approximately
5minutes. Both devices achieved >4 log10 inactivation for when car-
riers were placed in direct line of site. For C difficile, both devices
achieved a statistically similar kill; however, the duration of expo-
sure was different (approximately 43 minutes for Tru-D and
10 minutes for Optimum). Cadnum et al studied the effectiveness
of 2 UV-C devices (Tru-D and Optimum) to kill MRSA and C difficile
and reported there was no difference in log10 pathogen reductions
on experimentally contaminated steel carrier disks irradiated at
~1.22 m between the 2 devices. For MRSA, a >3 log10 reduction was
achieved with 5-minute exposure, whereas for C difficile increas-
ing exposure led to increasing kill (20-minute exposure required
to achieve a reduction of approximately 2 log10).26
Havill et al compared UV-C (Tru-D) with HPV (Bioquell) for de-
contamination of patient rooms by assessing aerobic bacteria present
on high-touch surfaces (ie, bedside rail, overbed table, television
remote, bathroom grab bar, toilet seat) and by using carrier disks
contaminated with C difficile.29 The percent of sites yielding aerobic
growth pre- and postdecontamination was as follows: 91% to 49%
for UV-C and 93% to 7% for HPV, respectively. For C difficile, UV-C
achieved an average reduction of 2.2 log10 (range, 1.7-3.0), whereas
HPV achieved a 6 log10 reduction. Importantly, UV-C showed sub-
stantially better results for the sites in the patient room (eg, overbed
table) than in the patient bathroom (eg, toilet seat).
HPV (Bioquell) has been used to decontaminate rooms previ-
ously occupied by patients with Lassa fever63 and Ebola viral
disease64; however, before and after viral cultures were not
performed.
CLINICAL TRIALS USING HPV ROOM
DECONTAMINATION DEVICES
Multiple clinical trials have assessed the efficacy of UV or hy-
drogen peroxide room decontamination units for reducing HAIs
(Table 4).56,65-74
Several studies warrant detailed discussion, including the studies
by Passaretti et al,67 Pegues et al,73 and Anderson et al.74 Passaretti
et al performed a 30-month prospective cohort (before-after study)
intervention using a hydrogen peroxide vapor device (Bioquell) on
6 high-risk units in a 994-bed tertiary care hospital.67 Patients ad-
mitted to rooms decontaminated using HPV were 64% less likely
to acquire anymultidrug-resistant pathogen (IRR, 0.36; P < .001) and
80% less likely to acquire VRE (IRR, 0.20; P < .001). The risk of ac-
quiring C difficile, MRSA, and multidrug-resistant gram-negative
bacilli was reduced, but not significantly. The proportion of rooms
environmentally contaminated with multidrug-resistant organ-
isms was reduced significantly on the HPV units (RR, 0.65; P = .03).
Pegues et al performed a prospective cohort (before-after study)
in 3 hematology-oncology units to assess the efficacy of a UV-C
device (Optimum) to reduce C difficile infection.73 Importantly, rooms
were disinfected with bleach prior to use of the UV-C device.
A significant association between UV-C use and a decline in
C difficile infection incidence was noted on study units (IRR, 0.49;
95% confidence interval, 0.26-0.94; P = .03) but not on the nonstudy
units (IRR, 0.63; 95% confidence interval, 0.38-1.06; P = .08).
Importantly, hand hygiene compliance, which was monitored
by observation, and room cleaning compliance, which was
Table 3
Effectiveness of hydrogen peroxide systems on reducing multidrug-resistant organisms in contaminated patient rooms




(% surfaces positive) Reduction (%)
French, 200449 HPV (Bioquell) MRSA 72 (61/85) 1 (1/85) 98
Bates, 200550 HPV (Bioquell) Serratia marcescens 10 (4/42) 0 (0/25) 100
Jeanes, 200551 HPV (Bioquell) MRSA 36 (10/28) 0 (0/50) 100
Hardy, 200752 HPV (Bioquell) MRSA 24 (7/29) 0 (0/29) 100
Otter, 200753 VHP (Bioquell) MRSA, GNR 40 (12/30), 10 (3/30) 3 (1/30), 0 (3/30) 93, 100
Shapey, 200854 HP dry mist (Sterinis) Clostridium difficile 23.6 (48/203) 3.4 (7/203) 86
Dryden, 200855 VHP (Bioquell) MRSA 27.6 (8/29) 3.4 (1/29) 88
Boyce, 200856 VHP (Bioquell) C difficile 25.6 (11/43) 0 (0/37) 100
Bartels, 200857 HP dry mist (Sterinis) MRSA 28.6 (4/14) 0 (0/14) 100
Otter, 201058 HPV (Bioquell) GNR 48 (10/21) 0 (0/63) 100
GNR, Gram-negative rod; HP, hydrogen peroxide; HPV, hydrogen peroxide vapor; MRSA, methicillin-resistant Staphylococcus aureus.
Adapted from Felagas JE, et al. J Hosp Infect 2011;78:171-7.
Table 4
Clinical trials using UV or HP devices for terminal room disinfection to reduce health care–associated infections








Boyce, 200856 Before-after (CDI high-incidence
wards)
Community hospital HPV (Bioquell) CDI 2.28 to 1.28 per 1,000 Pt days (P = .047) No No NA
Cooper, 201165 Before-after (2 cycles) Hospitals HPV (NS) CDI Decreased cases (incidence NS) No No Yes
Levin, 201366 Before-after Community hospital UV-PX, Xenex CDI 9.46 to 4.45 per 10,000 Pt days (P = .01) No No Yes
Passaretti, 201367 Prospective cohort
(comparison of MDRO acquisition;
admitted to rooms with or without
HPV decontamination)





2.3 to 1.2 (P = .30)
7.2 to 2.4 (P < .01)
2.4 to 1.0 (P = .19)
12.6 to 6.2 per 1,000 Pt days (P < .01)
No No No
Manian, 201368 Before-after Community hospital HPV (Bioquell) CDI 0.88 to 0.55 cases per 1,000 Pt days
(P < .0001)
Yes No No





0.79 to 0.65 per 1,000 Pt days (P = .02)
0.45 to 0.33 per 1,000 Pt days (P = .007)
0.90 to 0.73 per 1,000 Pt days (P = .002)
0.52 to 0.42 per 1,000 Pt days ((P = .04)
2.67 to 2.14 per 1,000 Pt days (P < .001)
No Yes Yes






9.0 to 5.3 per 10,000 Pt days (P < .001) Yes No Yes
Miller, 201571 Before-after Urban hospital UV-PX, Xenex CDI 23.3 to 8.3 per 10,000 Pt days (P = .02) No No Yes
Nagaraja, 201572 Before-after Academic center UV-PX, Xenex CDI 1.06 to 0.83 per 1,000 Pt days (P = .06) No No No
Pegues, 201573 Before-after Academic center CV-C (Optimum) CDI 30.34 to 22.85 per 10,000 Pt days
(IRR = 0.49; 95% CI, 0.26-0.94; P = .03)
Yes Yes No
Anderson, 201574 RCT 9 hospitals UV-C (Tru-D) MRSA, VRE, CDI 51.3 to 33.9 per 10,000 Pt days
(P = .036)*
Yes Yes No
CDI, Clostridium difficile infection; CI, confidence interval; EVS, environmental service; GNB, gram-negative bacteria; HAI, health care–associated infections; HH, hand hygiene; HP, hydrogen peroxide; HPV, hydrogen peroxide
vapor; IRR, incidence rate ratio; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; NS, not stated; Pt, patient; RCT, randomized clinical trial; UV, ultraviolet light;
UV-PX, ultraviolet light, pulsed-xenon device; VRE, vancomycin-resistant enterococci.
*Outcome includes new colonization plus HAI.
monitored using 3M™ Clean-Trace Surface ATP test device (3M, St.
Paul, MN), were similar in the baseline and intervention periods (D.
Pegues, personal communication, October 16, 2015).
The study by Anderson et al is the first randomized clinical trial
to assess a no touch method (UV-C; Tru-D) for terminal room
disinfection.74 Specifically, this was a prospective, multicenter, cluster-
randomized, crossover trial in 9 hospitals which evaluated 3
strategies for enhanced terminal room disinfection: standard qua-
ternary ammonium compound plus UV-C, bleach alone, and bleach
plus UV-C. Patients colonized or infected with MRSA, VRE, or with
C difficile infection were considered seed rooms with exposed pa-
tients being patients subsequently admitted to a seed room. Exposed
patients were followed for the development of an HAI caused by a
target pathogen. Compliance with hand hygiene and terminal room
cleaning were measured, and there were no differences in these po-
tential confounders among the baseline group (quaternary
ammonium compound alone) and the 3 intervention arms. The study
showed that enhanced room decontamination strategies (ie, bleach
or UV-C decontamination) decreased the clinical incidence of ac-
quisition of target multidrug-resistant organisms (ie, MRSA, VRE,
C difficile) by approximately 10%-30% (P = .036).
No touch room disinfection devices have been used as a com-
ponent to control health care–associated outbreaks.6,50,51,55,56,58,75-77
The outbreaks involved S aureus, multidrug-resistant gram-negative
bacilli, C difficile, and A baumannii plus MRSA. The device used in
most cases was a HPV system (Bioquell).
DEMONSTRATING THAT NO TOUCH ROOM DECONTAMINATION
UNITS REDUCE HAI
One may assess the efficacy of no touch room decontamina-
tion using a hierarchy of research methods. In increasing order of
demonstrating efficacy to reduce HAIs, the following methods may
be used: (1) in vitro studies demonstrating that the no touch device
eliminates or reduces relevant pathogens (eg, MRSA, VRE, C difficile,
A baumannii, multiple drug-resistant gram-negative bacilli); (2)
studies in used patient rooms demonstrating that the no touch device
eliminates or reduces relevant pathogens inoculated onto appro-
priate carriers and placed throughout the patient room; (3) studies
following patient discharge in patient rooms demonstrating elim-
ination or reduction of relevant pathogens on naturally contaminated
environmental surfaces; (4) before-after studies demonstrating that
the no touch system reduces HAI incidence; (5) cross-over studies
with multiple sites or multiple cross-over points so as to mini-
mize the potential biases in a single cross-over study (eg, before-
after study); and (6) randomized clinical trials demonstrating that
the no touch device reduces HAI incidence.
In clinical trials (ie, before-after studies, cross-over studies, ran-
domized clinical trials), it is important that potential confounders
be measured, especially hand hygiene compliance and compli-
ance with surface cleaning. In all clinical trials, the only test variable
should be the use of the no touch device (ie, multiple interven-
tions should not be undertaken or if undertaken should be
standardized across study arms).
As previously noted, UV device may vary because of differ-
ences in UVwavelength, bulb size, energy output, ability to measure
energy delivery, and cost. Similarly, hydrogen peroxide systems differ
with regard to concentration, use of other microbicides, method of
injecting hydrogen peroxide into a room or space, and cost. For these
reasons, infection control professionals should review the peer-
reviewed literature and choose for purchase only devices with
demonstrated bactericidal capability as assessed by the carrier test
method or ability to disinfect actual patient rooms. Ultimately, one
should choose only devices that have demonstrated the ability to
reduce HAIs.
Further, infection control professionals should be aware of the
advantages and disadvantages of both UV and hydrogen peroxide
systems.22,23 The major advantages of both systems are the ability
to consistently decontaminate hospital room surfaces. Both systems
are residual free. The major disadvantage of both systems is that
they may only be used for terminal disinfection. Neither system
will physically clean a room (eg, remove dust or stains), hence
room cleaning must precede disinfection. Other differences include
the following: (1) UV systems require a shorter delivery time; (2)
UV systems can only inactivate pathogens in direct or indirect line
of site (ie, they may not effectively decontaminate all surfaces in
adjacent rooms, such as bathrooms); (3) hydrogen peroxide systems
require that the HVAC system be sealed; and (4) hydrogen perox-
ide systems have demonstrated greater kill against spore-forming
organisms (although the clinical impact requires further
studies).
For the future, additional well-designed randomized clinical trials
of UV devices and hydrogen peroxide systems would further define
their potential benefits. It would be very useful to compare a UV
light device with a hydrogen peroxide device in a randomized clin-
ical trial. Randomized clinical trials would also allow calculation of
the cost-effectiveness of these devices. However, logistic and cost
reasons are likely to preclude randomized clinical trials. Rather, de-
cisions on use of these devices will need to be based on consistent
demonstration of effectiveness in killing pathogens as previously
detailed and quasi-experimental studies.
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